Breaking News, Collaborations & Alliances

HanAll Signs Exclusive Licensing Agreement with Turn Biotechnologies

The terms grant HanAll the right to utilize Turn Bio's Epigenetic Reprogramming of Aging (ERATM) technology.

Author Image

By: Charlie Sternberg

Associate Editor

HanAll Biopharma Co. Ltd. has signed an exclusive licensing agreement with Turn Biotechnologies Inc., a pre-clinical stage biopharmaceutical company focused on cellular repair through epigenetic reprogramming—expanding their relationship, which began in 2022 when HanAll made an initial investment in Turn Bio.   The terms grant HanAll the right to utilize Turn Bio’s Epigenetic Reprogramming of Aging (ERATM) technology to research, develop, manufacture, and commercialize medicines for opht...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters